The Impact of Interleukin-17 Inhibitors on Major Adverse Cardiovascular Events in Psoriasis or Psoriatic Arthritis Patients Naive to Biologic Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Ruoning Ni; Jiayi Zheng; Jimmy Varghese; Bharat Kumar

doi:10.7759/cureus.60980

Back

The Impact of Interleukin-17 Inhibitors on Major Adverse Cardiovascular Events in Psoriasis or Psoriatic Arthritis Patients Naive to Biologic Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Journal article

Open access

Peer reviewed

The Impact of Interleukin-17 Inhibitors on Major Adverse Cardiovascular Events in Psoriasis or Psoriatic Arthritis Patients Naive to Biologic Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Ruoning Ni, Jiayi Zheng, Jimmy Varghese and Bharat Kumar

Curēus (Palo Alto, CA), Vol.16(5), e60980

05/24/2024

DOI: 10.7759/cureus.60980

PMCID: PMC11193915

PMID: 38910708

Files and links (1)

url

https://doi.org/10.7759/cureus.60980View

Published (Version of record) Open Access

Abstract

The objective of this systematic review is to determine the effects of IL-17 inhibitors on major adverse cardiovascular events (MACEs) in patients with either psoriasis (PsO) or psoriatic arthritis (PsA). A systematic literature search in three databases (Medline, Embase, and the Cochrane Library for Randomized Controlled Trials) was conducted on December 7, 2022 for randomized controlled trials of patients with PsO/PsA treated with IL-17 inhibitors that reported confirmed MACEs. Two reviewers screened titles and abstracts and identified papers for full-text review. Exclusion criteria included trials that included the previous use of biological disease-modifying anti-rheumatic drugs. The Mantel-Haenszel random-effect method was utilized to calculate risk ratios and heterogeneity was measured by chi(2) test and I2 statistics. Funnel plot analysis was undertaken to detect potential publication bias. Of the 919 references identified, nine RCT studies were included in the meta-analysis (n=2,096 patients). There was no statistically significant correlation between the use of IL-17 inhibitors and change in risk of MACEs (Risk Ratio 0.56; 95% CI 0.15 to 2.14; p = 0.40). Subgroup analysis of secukinumab or ixekizumab also did not demonstrate these changes. Additionally, there was no detectable dose-dependent effect of IL-17 inhibitors. In conclusion, IL17 inhibitor use is not correlated with a change in MACE risk in patients with PsO/PsA who previously did not receive biologic disease-modifying anti-rheumatic drugs.

General & Internal Medicine

Life Sciences & Biomedicine

Medicine, General & Internal

Science & Technology

Details

Title: Subtitle: The Impact of Interleukin-17 Inhibitors on Major Adverse Cardiovascular Events in Psoriasis or Psoriatic Arthritis Patients Naive to Biologic Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Creators: Ruoning Ni - University of Iowa
Jiayi Zheng - The Wright Center for Graduate Medical Education
Jimmy Varghese - The Wright Center for Graduate Medical Education
Bharat Kumar - University of Iowa
Resource Type: Journal article
Publication Details: Curēus (Palo Alto, CA), Vol.16(5), e60980
DOI: 10.7759/cureus.60980
PMID: 38910708
PMCID: PMC11193915
NLM abbreviation: Cureus
ISSN: 2168-8184
eISSN: 2168-8184
Publisher: Springer Nature
Number of pages: 11
Language: English
Date published: 05/24/2024
Academic Unit: Immunology; Internal Medicine
Record Identifier: 9984946617902771

Metrics

5 Record Views